PDCD1 and non-small cell lung carcinoma: Similarly, in non–small cell lung cancer (NSCLC), anti–PD-1 therapy can induce neoantigen-specific T cell responses, and neoantigens have been associated with durable clinical benefits in patients with NSCLC and melanoma treated with checkpoint blockade (44).